Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient's life ...
Epilansis: A NextGen, Cloud-based Epidemiology Platform for Faster, Smarter Market Decisions
With the healthcare landscape shifting rapidly, teams across biopharma, consulting, med-tech, and healthcare strategy face a common bottleneck: turning scattered epidemiology data, literature, real wo ...